Evidence map›Paper›PMID 22789625›Full record

ReviewHuman immunology2012

HLA class I: an unexpected role in integrin β4 signaling in endothelial cells.

Xiaohai Zhang, Elaine F Reed

Abstract readReview
In one paragraph

Review in Human immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Re-Evaluating the Transplant Glomerulopathy Lesion-Beyond Donor-Specific Antibodies.Transplant international : official journal of the European Society for Organ Transplantation · 2024
    Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Phosphorylated S6 kinase and S6 ribosomal protein are diagnostic markers of antibody-mediated rejection in heart allografts.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2015
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Xiaohai ZhangUCLA Immunogenetics Center, Department of Pathology, David Geffen School of Medicine, University of California, 1000 Veteran Ave., Los Angeles, CA 90095, United States. xiaozhang@mednet.ucla.edu
Elaine F Reed
University of California, Los Angeles · US

Funding

Development of Transplant Strategies Uniquely Responsive to the Needs of ChildrenU01AI077821 · NIAID · EMORY UNIVERSITY · PI KIRK, ALLAN D. · 2008 to 2012
$7.5M
Anti-MHC Effects on EndotheliumR01AI042819 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI REED, ELAINE F · 1999 to 2014
$4.0M
Anti-HLA Antibody Activation of Endothelial Cells in Cardiac TransplantationR01HL090995 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI REED, ELAINE F · 2008 to 2010
$1.2M
NHLBI NIH HHS R01 HL 090995NHLBI NIH HHS R01 HL090995NIAID NIH HHS R01 AI 042819NIAID NIH HHS R01 AI042819NIAID NIH HHS U01 AI077821NIAID NIH HHS U01AI077821
6 · The paper itself

Abstract

The production of anti-donor antibodies to HLA class I and class II antigens following transplantation is associated with development of transplant vasculopathy and graft loss. Antibodies against HLA class I (HLA-I) molecules are thought to contribute to transplant vasculopathy by triggering signals that elicit the activation and proliferation of endothelial cells. The proximal molecular events that regulate HLA-I dependent signal transduction are not well understood. We demonstrated a mutual dependency between HLA-I and integrin β4 to stimulate signal transduction and cell proliferation. Similarly, we found that integrin β4-mediated cell migration was dependent upon its interactions with HLA-I molecules. Since integrin β4 has been implicated in angiogenesis and tumor formation, associations between integrin β4 and HLA-I may play an important role in cancer. Further characterization of interactions between HLA-I and integrin β4 may lead to the development of therapeutic strategies for the treatment and prevention of chronic allograft rejection and cancer.

Indexed as

Signal TransductionAntibodiesCell ProliferationCell SurvivalDisease ProgressionEndothelial CellsHistocompatibility Antigens Class IHumansIntegrin beta4NeoplasmsNeuronsAntibodiesHistocompatibility Antigens Class IIntegrin beta4

Identifiers

PMID22789625
PMCPMC3485417
OpenAlexW2021410856

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.